StreetInsider.com News Articles

Form DEF 14A Silexion Therapeutics For: Oct 05

Mon, 05 Oct 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20261005/27148844.html

Form 8-K Silexion Therapeutics For: Sep 30

Wed, 30 Sep 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260930/27126000.html

Silexion doses first patient in Phase 2/3 pancreatic cancer trial

Wed, 30 Sep 2026 08:01:00 -0400

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced that the first patient has been dosed in its Phase 2/3 clinical trial of SIL204, an RNA interference therapy targeting locally advanced pancreatic cancer (LAPC). The treatment was administered at Tel Aviv Sourasky Medical Center in Israel, according to a company press release dated Sept. 30, 2026.

The trial is a prospective, randomized, controlled, multinational, open-label study evaluating SIL204 in combination with standard-of-care chemotherapy versus chemotherapy alone. The study begins with a safety run-in cohort of approximately 18 patients, followed by a randomized expansion cohort of approximately 166 patients. Eligible participants are newly diagnosed, treatment-naïve

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Wed, 30 Sep 2026 08:00:00 -0400

Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer

Integrated regimen combines direct EUS-guided intratumoral delivery to penetrate tumor stroma with subcutaneous dosing; first patient treated at Tel Aviv Sourasky Medical Center (Ichilov)

Grand Cayman, Cayman Islands and Ramat Gan, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the first patient worldwide has been successfully dosed in its Phase 2/3 clinical

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Wed, 30 Sep 2026 08:00:00 -0400

Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer

Integrated regimen combines direct EUS-guided intratumoral delivery to penetrate tumor stroma with subcutaneous dosing; first patient treated at Tel Aviv Sourasky Medical Center (Ichilov)

Form 424B3 Silexion Therapeutics

Tue, 29 Sep 2026 10:35:00 -0400

si-local-file:///var/storage/secattach/20260929/27119630.html

Form 8-K Silexion Therapeutics For: Sep 28

Tue, 29 Sep 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260929/27119601.html

Silexion Therapeutics exercises series E warrants for $837K

Tue, 29 Sep 2026 08:05:17 -0400

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced it has entered into definitive agreements for the exercise of certain outstanding series E warrants to purchase up to 3,216,928 ordinary shares at a reduced exercise price of $0.2603 per share.

The gross proceeds from the warrant exercise are expected to total $837,366.36, before placement agent fees and other offering expenses. The company said it intends to use the net proceeds for working capital and general corporate purposes. The offering was expected to close on or about Sept. 29, 2026, subject to customary closing conditions.

The ordinary shares issuable upon exercise of the warrants are registered

Silexion Therapeutics exercises series E warrants for $837K

Tue, 29 Sep 2026 08:05:17 -0400

The ordinary shares issuable upon exercise of the warrants are registered

Silexion Therapeutics Announces Exercise of Warrants

Tue, 29 Sep 2026 08:03:00 -0400

Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of $0.2603 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-298137). The

Silexion Therapeutics Announces Exercise of Warrants

Tue, 29 Sep 2026 08:03:00 -0400

Form SCHEDULE 13D/A Silexion Therapeutics Filed by: Moringa Sponsor, LP

Mon, 28 Sep 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260928/27114885.html

Form 8-K Silexion Therapeutics For: Sep 28

Mon, 28 Sep 2026 08:46:00 -0400

si-local-file:///var/storage/secattach/20260928/27110720.html

Silexion reports preclinical uptake data for cancer drug SIL204

Mon, 28 Sep 2026 08:31:29 -0400

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced preclinical findings from a translational study of its lead drug candidate, SIL204, showing the compound uses naturally occurring lipoproteins in the blood to enter cancer cells and suppress the KRAS oncogene.

The study, conducted without synthetic transfection reagents, found that human KRAS-driven cancer cells treated with SIL204 showed dose-dependent gene silencing when standard physiological serum lipids were present. When serum lipids were depleted, gene-knockdown efficiency declined significantly (P < 0.001), according to the company's statement. Adding external low-density lipoprotein (LDL) did not change silencing potency compared to complete serum alone, suggesting that normal circulating lipoprotein

Silexion reports preclinical uptake data for cancer drug SIL204

Mon, 28 Sep 2026 08:31:29 -0400

Silexion reports preclinical uptake data for cancer drug SIL204

Mon, 28 Sep 2026 08:31:29 -0400

Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers

Mon, 28 Sep 2026 08:30:00 -0400

Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown

Findings validate that physiological lipoprotein levels are sufficient for cellular entry without requiring artificial nanoparticles, supporting systemic administration in the Company's Phase 2/3 clinical program

Grand Cayman, Cayman Islands, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced positive new findings from an ongoing translational study evaluating the cellular uptake and gene-silencing mechanism of its

Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers

Mon, 28 Sep 2026 08:30:00 -0400

Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown

Form 8-K Silexion Therapeutics For: Sep 25

Fri, 25 Sep 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260925/27107583.html

Form PRE 14A Silexion Therapeutics For: Sep 25

Fri, 25 Sep 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260925/27107515.html

Form 8-K Silexion Therapeutics For: Sep 25

Fri, 25 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260925/27107387.html

Form DEFA14A Silexion Therapeutics

Wed, 16 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260916/27070264.html

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

Wed, 09 Sep 2026 09:00:00 -0400

Grand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that members of its management team will participate in the following industry and investor conferences in September 2026:

Oncology & Immunology Innovation Partnering & Licensing Summit
Presentation date: September 9, 2026
Location: Hotel Commonwealth, Boston, MA
Format: Presentation
Presenter: Dr. Mitchell Shirvan, Chief Scientific and Development Officer

8th Annual RAS-Targeted Drug Development Summit
Presentation date: September 10, 2026
Location: The Colonnade Hotel, Boston,

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

Wed, 09 Sep 2026 09:00:00 -0400

8th Annual RAS-Targeted Drug Development Summit
Presentation date: September 10, 2026
Location: The Colonnade Hotel, Boston,

Form DEF 14A Silexion Therapeutics For: Aug 24

Tue, 25 Aug 2026 08:37:00 -0400

si-local-file:///var/storage/secattach/20260825/26971415.html